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Abstract: The HIV-1 integrase enzyme is essential for integrating the viral DNA into the 
host chromosome. Infection is aborted in the absence of integration, making integrase an 
attractive antiviral target. Recently approved inhibitors of integrase bind tightly to integrase 
assembled in a nucleoprotein complex with the viral DNA ends (intasome), but have only 
low affinity for free integrase. High-resolution structures of HIV-1 intasomes are therefore 
required to understand the detailed mechanisms of inhibition and resistance. Although the 
structure of the HIV-1 intasome has not yet been determined, the structure of the related 
prototype foamy virus (PFV) intasome was recently solved. A new study [1] exploits the 
PFV structure to model the HIV-1 intasome. The model provides the most reliable picture 
to date of the active site region of the HIV-1 intasome and is an important advance in 
studies of inhibition of this essential HIV-1 enzyme. 
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Integrase catalyzes the key DNA cutting and joining reactions responsible for integrating retroviral 
DNA into cellular DNA, where it is replicated along with host DNA during multiple cycles of cell 
division and serves as the template for transcription of progeny viral RNAs (reviewed in [2]). The viral 
DNA is synthesized by reverse transcription in the cytoplasm, after which it remains associated with 
other viral and cellular proteins as a large nucleoprotein complex called the preintegration complex 
(PIC). The PIC is later transported to the nucleus where integrase within the PIC splices the viral DNA 
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into the host genome. Integrase normally functions as part of the PIC, but integrase alone is able to 
carry out the key DNA cutting and joining steps in vitro with simple DNA substrates that mimic the 
viral  DNA  ends  in  the  presence  of  a  divalent  metal  ion.  In  the  first  of  these  reactions,  3'  end 
processing, integrase removes two nucleotides from each 3' end of the viral DNA. In the second step, 
DNA strand transfer, the 3' hydroxyls of the terminal adenosine exposed by 3' end processing attack a 
pair of phosphodiester bonds at the site of integration into target DNA. In the case of HIV-1, the sites 
of integration on the two target DNA strands are separated by five nucleotides resulting in a five base 
pair duplication of target DNA sequence flanking the integrated viral DNA after repair of the resulting 
integration  intermediate  by  cellular  enzymes.  A  key  nucleoprotein  intermediate  is  the  intasome, 
comprised  of  a  tetramer  of  integrase  that  stably  bridges  a  pair  of  viral  DNA  ends  [3].  Recently 
developed integrase strand transfer inhibitors (INSTI), such as Raltegravir and Elvitegravir, bind to the 
intasome and have only weak affinity for free integrase in the absence of bound viral DNA ends.  
High-resolution structures of the HIV-1 intasome are therefore required to understand the mechanism 
of inhibition and resistance, and to design improved drugs. 
Structural studies of retroviral integrases have been fraught with obstacles and progress has been 
painfully slow. Although it is well over a decade since the structures of all three domains of HIV-1 
integrase were determined [4–7], the first structure of a retroviral intasome—that of prototype foamy 
virus (PFV)—has only recently been solved [8]. The first problem was the poor solubility of intact  
HIV-1 integrase that was partially overcome by studying individual domains rather than the intact 
enzyme.  A  mutation  was  also  introduced  into  the  catalytic  domain  to  improve  its  solubility  and 
facilitate crystallization [9]. Later, two domain structures were determined for both the N-terminal 
domain  and  catalytic  domain  and  for  the  C-terminal  and  catalytic  domain  (reviewed  in  [10]). 
Structures of different retroviral integrases exhibited major differences in the spatial configuration of 
the catalytic and C-terminal domain suggesting that bound viral DNA is required to constrain the 
active integrase multimer in the intasome. Numerous models of the intasome have been proposed 
based  on  these  partial  structures,  but  the  PFV  intasome  structure  demonstrated  that  all  of  them  
are wrong. 
The breakthrough in structural studies of intasomes came from the discovery that PFV integrase 
displays much more favorable properties for biophysical studies than its HIV-1 counterpart [11]. It 
exhibits better solubility and efficiently catalyzes coupled integration of pairs of short oligonucleotides 
mimicking the viral DNA ends in vitro. In contrast, the products of in vitro reactions with HIV-1 
integrase are mainly insertions of single viral DNA ends into one strand of target DNA, a reaction that 
lacks the full fidelity of integration in vivo. The ability of PFV integrase to support efficient coupled 
integration of pairs of viral DNA ends was critical to the success of the structural studies because 
intasomes  only  assemble  under  conditions  that  support  coupled  integration.  Assembly  of  HIV-1 
intasomes also requires much longer DNA that is unsuitable for crystallization. The crystal structure of 
the PFV intasome [8] provided the first view of any retroviral intasome. The structure could not have 
been predicted based on the structure of the HIV-1 integrase protein domains alone because the viral 
DNA acts as a glue that holds the intasome together with the integrase domains  adopting a very 
different spatial arrangement compared with the earlier structures of the protein alone (Figure 1). An 
inner pair of integrase subunits within the tetramer in the PFV intasome is responsible for all the 
protein-protein and protein-DNA contacts that hold the intasome together. The N-terminal domains Viruses 2010, 2                         
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(NTD)s and C-terminal domains (CTD)s of the outer pair of integrase subunits are disordered and their 
functional roles, if any, are unclear. 
Figure 1. Schematic depiction of the arrangement of integrase domains in the prototype 
foamy virus (PFV) intasome. The four subunits in the integrase tetramer are distinguished 
by color. The catalytic core domain (CCD), C-terminal domain (CTD), N-terminal domain 
(NTD), and N-terminal extension domain (NED) of the cyan colored subunit are labeled. 
DNA is shown in red. The protein-protein and protein-DNA contacts that hold the tetramer 
together are all contributed by the inner two subunits (colored cyan and green). The CTD, 
NTD and NED of the outer two subunits (colored yellow and magenta) are disordered. 
 
 
Prior to the determination of the PFV intasome structure, the structures of the Tn5 transposase [12] 
and Mos 1 [13] transposase were the only structures of an integrase or transposase in complex with 
DNA and they provided the best available scaffold for modeling the active site of the HIV-1 intasome. 
These  structures  are  useful  for  modeling  the  engagement  of  DNA  with  the  active  site  of  HIV-1 
integrase, but are too different from retroviral integrases to model the HIV-1 intasome; the active unit 
is  a  dimer  and  structural  similarity  is  limited  to  the  catalytic  domain.  PFV  integrase  shares  less  
than 20% sequence identity with HIV-1 integrase and has an N-terminal extension domain (NTE) that 
is not found in HIV-1 integrase. However, the three PFV integrase domains in the PFV intasome 
structure that are shared with HIV-1 integrase have essentially the same structure as the isolated HIV-1 
integrase domains. Therefore, the PFV intasome structure represents a reliable scaffold onto which to 
model the HIV-1 intasome. The linkers between the three domains of HIV-1 integrase are shorter than 
in the PFV counterpart, but are sufficiently long to allow mapping of the HIV-1 integrase domains on 
the PFV intasome. Krishnan et al. [1] have used the PFV intasome structure and the partial structures 
of HIV-1 integrase to build a model of the HIV-1 intasome.  Viruses 2010, 2                         
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The model of the HIV-1 intasome provides a platform for understanding the mechanism of INSTIs 
such as Raltegravir and Elvitegravir. Like the structure of the PFV intasome complexed with INSTIs, 
inhibitor binding to the HIV-1 intasome is predicted to displace the 3' end of the viral DNA from the 
active  site  making  it  unavailable  as  the  nucleophile  to  attack  the target  DNA  in  the  DNA  strand 
transfer reaction. Coplanar INSTI oxygen atoms engage the divalent metal ions and the halobenzyl 
moieties of the INSTI stack against the penultimate cytosine of the joining strand, forcing the 3-OH of 
the terminal adenine to move away from the active site carboxylates and divalent metal ions. The 
major contact points between DNA bases and protein residues are conserved between PFV and HIV; 
hence, the mode of inhibitor binding is unlikely to be very different. A considerable body of data has 
accumulated on mutations that confer resistance to INSTIs and secondary mutations that improve viral 
fitness in the presence of primary resistance mutations (reviewed in [14,15]). However, only a small 
number of these mutations occur at residues that directly contact inhibitor in the HIV-1 intasome 
model.  Modeling  further  away  from  the  active  site  becomes  more  complicated due  to  divergence 
between the PFV and HIV-1 integrases. Clearly, actual structures of the HIV-1 intasome are required 
to  thoroughly  understand  resistance  mechanisms.  Nevertheless,  the  new  model  is  a  major  step  
forward  and  offers  the  clearest  view  to  date  on  the  molecular  mechanism  of  this  novel  class  of  
HIV-1 inhibitors.  
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